On July 28, Navan, Inc. rose 6.75% in regular trading, trading at $24.765/share, with turnover of $17.76 million. The stock continued its upward trajectory fueled by a recent enterprise contract win and broader sector strength.
On the news front, biopharmaceutical company Evotec recently announced the selection of Navan's platform to manage its global corporate travel and expense program. Evotec will deploy the platform across Germany, the UK, the US, Italy, and France to consolidate travel and expense management into a single system with automated reconciliation. Financial terms of the deal were not disclosed. This marks another significant enterprise client addition following wins with PCL Construction, Opella, and Kiabi in recent months.
Additionally, the Hotels, Resorts and Cruise Lines sector posted broad gains, with Booking Holdings rising 4.27%, Marriott up 1.49%, and Carnival up 1.36%, providing sector-wide tailwinds. The stock also benefits from sustained analyst optimism, with Morgan Stanley maintaining an overweight rating and a $33 price target following a strong fiscal Q1 earnings beat in June.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments